ABSORPTION AND DISPOSITION OF A FIRST-IN-CLASS ALTERNATIVE COMPLEMENT PATHWAY FACTOR B INHIBITOR: IPTACOPAN
Back
Abstract Number
WCN23-0371
Categories
Chronic Kidney Disease, Hypertension, Diabetes and CVD
Topic - Chronic Kidney Disease, Hypertension, Diabetes and CVD
Other CKD
Topic - AKI, Electrolytes, Acid-base Disorders, Tropical Diseases, RPGN and Pregnancy
Topic - Kidney Failure (Former ESKD), incl. Dialysis, Transplantation, Conservative Care
Topic - Special Covid-19
Topic - Education
Abstract Title
ABSORPTION AND DISPOSITION OF A FIRST-IN-CLASS ALTERNATIVE COMPLEMENT PATHWAY FACTOR B INHIBITOR: IPTACOPAN
Co-authors
Schmouder, R.(1)*;Shah, B.(1);Hackling, M.(1);James, A.D.(2);Nidamarthy, P.K.(3);Kulmatycki, K.(4);
ie:
Azwin Z.1, Siti Y.1, John D.2
Institution
(1)Novartis Pharmaceuticals Corporation, Translational Medicine, East Hanover, United States;(2)Novartis Pharma Ag, Translational Medicine, Basel, Switzerland;(3)Novartis Healthcare Pvt. Ltd, Biostatistics & Pharmacometrics, Hyderabad, India;(4)Novartis Institutes Of Biomedical Research, Translational Medicine, Cambridge, United States;
E-Poster
https://storage.unitedwebnetwork.com/files/1041/e46c0b43bca6c6d2dac42811eeeae201.pdf
Audio File
https://storage.unitedwebnetwork.com/files/1041/bafe0ae0777b268a5140d8ecf5e3ba6a.mp3
if any